Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology - United Kingdom
doi 10.1002/hon.106_2630